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Inborn errors of immunity to infection: 
the rule rather than the exception
 
Jean-Laurent Casanova and Laurent Abel
 
The immune system’s function is to protect against microorganisms, but 
infection is nonetheless the most frequent cause of death in human history. 
Until the last century, life expectancy was only 
 
 
 
25 years. Recent increases in 
human life span primarily reflect the development of hygiene, vaccines, and 
anti-infectious drugs, rather than the adjustment of our immune system to 
coevolving microbes by natural selection. We argue here that most individuals 
retain a natural vulnerability to infectious diseases, reflecting a great diversity 
of inborn errors of immunity.
 
The burden of infection in 
human history
 
Humans are prone to a multitude of
endemic and epidemic infectious dis-
eases (1), which have been the leading
cause of death throughout history (2).
In mid–19th century England, 
 
 
 
60%
of deaths were due to infectious dis-
eases and this proportion was even
higher in previous centuries, especially
during epidemics. Mortality curves dem-
onstrate that the burden of infec-
tious diseases was high, with life ex-
pectancy averaging 
 
 
 
25 years from the
Palaeolithic period until the Industrial
Revolution (Fig. 1). Even in Europe,
only 35% of people reached the age of
40 at the end of the 19th century. Life
expectancy has now reached 80 years
in these regions. The current high
mortality rates in the poorest countries,
such as Mozambique, may be seen as
an unfortunate testimony to our com-
mon past (Fig. 1). On a historical scale,
the increase in life expectancy is recent
and is a major contributor to the ongo-
ing population explosion. Increased life
expectancy primarily reflects progress
in the control of infectious diseases
based on three factors: the develop-
ment of hygiene, beginning in the
mid–19th century (preventing the
transmission of infection); the develop-
ment of vaccines, beginning in the late
19th century (preventing disease in
infected individuals); and the devel-
opment of anti-infectious drugs, be-
ginning in the early 20th century (pre-
venting death in patients with clinical
disease). The relative contributions of
these three factors depend on the dis-
ease in question.
 
Inherited predisposition to infection
 
A complex interplay between environ-
mental (microbial and nonmicrobial)
and human (genetic and nongenetic)
factors determines immunity to infec-
tion and the resulting clinical outcome
of infection. By definition, humans dy-
ing of infection have impaired immu-
nity to infection (immunodeficiency).
Accumulating evidence suggests that
human genetic factors play a particu-
larly important role in immunodefi-
ciency and susceptibility to infectious
diseases (3, 4). The increase in life ex-
pectancy observed in the 20th century
occurred despite the retention of poor
immunity to particular infectious agents
in most individuals (Fig. 1). There has
been no sudden natural selection of
high-quality immune system genes
worldwide: this persistent immunode-
ficiency has simply been masked by
medical progress. Investigations into
natural host variability in the develop-
ment of infectious diseases began in the
early 20th century with the discovery
by Charles Nicolle of the coexistence
of symptomatic and asymptomatic in-
fections in naive populations (5). The
first evidence supporting the hypothesis
that host variability and immunodefi-
ciency were hereditary originated from
observations of the ethnic or familial
aggregation of both rare and common
infections, which in some kindreds
even followed a Mendelian (mono-
genic) pattern of inheritance (6, 7).
Epidemiological studies of adopted in-
dividuals also showed that predisposi-
tion to infectious diseases was largely
inherited, paradoxically more so than
in diseases associated with less well-
known environmental risk factors, such
as cancer (8). Finally, studies comparing
the concordance rate of infectious dis-
eases between monozygotic and dizy-
gotic twins have also implicated host
genetic background in susceptibility to
disease (3, 6).
 
Conventional primary immunodeficiencies
 
There have been three independent
lines of molecular and cellular investi-
gation in human genetics of infectious
diseases: the study of rare primary im-
munodeficiencies (Mendelian predis-
position to infectious diseases), that of
complex (multigenic, non-Mendelian)
predisposition or resistance to common
infectious diseases, and that of com-
mon Mendelian resistance to infection.
Compelling evidence for the heritable
nature of impaired immunity was first
provided by primary immunodeficien-
cies (9). The first primary immunodefi-
ciency was described in 1952, but it was
not until 1954 that this disease, Bruton’s
agammaglobulinemia, was found to be
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X-linked and recessive (10). The classi-
fication of primary immunodeficiencies
is currently based on immunological
phenotype and mode of inheritance (7,
11). At least 200 primary immunodefi-
ciencies are known, most of which
have a prevalence of less than 1 per
50,000 births. Conventional primary
immunodeficiencies are typically rare,
recessive Mendelian disorders that di-
rectly affect leukocytes. They present
during childhood as a vulnerability to
multiple, recurrent, life-threatening in-
fections by both weakly virulent oppor-
tunist microorganisms and more viru-
lent pathogens. Conventional primary
immunodeficiencies are suspected on
infectious grounds but were historically
defined and are currently diagnosed on
immunological grounds. Reticular dys-
genesia is the most striking and severe
form of primary immunodeficiency
known (12). This exceedingly rare au-
tosomal recessive disease, of unknown
genetic etiology, is characterized by a
total lack of granulocytes and lympho-
cytes. Patients with reticular dysgenesia
are vulnerable to almost all microorgan-
isms and die within a few weeks or
months of birth in the absence of he-
mopoietic stem cell transplantation.
 
Nonconventional primary 
immunodeficiencies
 
Inborn errors of immunity are not lim-
ited to conventional primary immuno-
deficiencies, which are associated with
overt immunological phenotypes and
multiple infectious phenotypes. About a
dozen intriguing Mendelian clinical
syndromes marked by a predisposition
to a single type of infection are known
(4). These nonconventional primary
immunodeficiencies may be recessive
or dominant and may or may not affect
cells derived from the hemopoietic
lineage. Typically, no immunological
abnormality is detected before the dis-
ease-causing gene is identified. Pre-
dispositions to viruses include the syn-
drome of epidermodysplasia verruciformis,
characterized by disseminated cutaneous
warts caused by oncogenic papillomavi-
ruses. The discovery that mutations in
 
EVER1
 
 and 
 
EVER2
 
, two genes of
unknown function that are normally
expressed in keratinocytes, were the
cause of epidermodysplasia verrucifor-
mis, opened a promising field of re-
search (13). Predispositions to bacteria
include the syndrome of Mendelian
susceptibility to mycobacterial diseases
(MSMD) in patients with mutations in
the interleukin-12–interferon-
 
 
 
 cytokine
circuit and infections caused by weakly
virulent mycobacteria (14–16). Studies
of patients with MSMD led to the dis-
covery that infectious diseases caused by
more virulent pathogens can also be
specifically favored by a Mendelian pre-
disposition. In three unrelated families,
patients with interleukin-12 receptor
 
 
 
1 (IL-12R
 
 
 
1) deficiency, a genetic
cause of MSMD, were found to suffer
from severe tuberculosis in the absence
of prior infection by weakly virulent
mycobacteria (17). These three families
are the first examples of a truly Mende-
lian predisposition to bona fide human
tuberculosis. They provide proof of
principle that common infectious dis-
eases in otherwise healthy individuals
may reflect Mendelian predisposition.
 
Major susceptibility genes
 
The proportion of patients suffering
from infectious diseases due to Mende-
lian predisposition is unknown. Recent
years have seen the emergence of the
related concept of major genes, defined
as genes whose common mutations
(polymorphisms) exert an effect strong
enough to be detected in complex seg-
regation studies, genome-wide linkage
scans, or both. Some of these genes
may even correspond to solitary loci,
exerting a nearly Mendelian impact (6).
The first identified major gene predis-
posing to infectious diseases in humans
controls susceptibility to leprosy, a dis-
ease caused by the bacterium 
 
Mycobacte-
rium leprae
 
. A complex segregation
study performed in 1988 showed that
human genetic predisposition to lep-
rosy depends on a major gene (18),
which was localized to a candidate re-
gion on 6q25 using a genome-wide
Figure 1. Mortality curves at various periods of human history, from the Palaeolithic period 
( 10,000 BCE) to modern times (2000 CE). Contemporary data for the UK and Mozambique 
are available from the WHO site (www.who.int/topics/global_burden_of_disease). Older data were 
obtained from the book by John Cairns (2). Life tables for the Palaeolithic and Neolithic periods are 
based on skeleton examinations, assuming that 60% of newborn infants survived to the age of five, 
because few very young skeletons were found in the burial grounds. The gradual adjustment of the 
immune system by natural selection did not increase life expectancy until the end of the 19th century, 
due to the coevolution of microorganisms and the emergence of new infectious threats. Thus, the 
increase in life expectancy in the 20th century does not reflect the sudden and global natural selection 
of high-quality immune genes. The area between the four ancient curves and the curve for the UK in 
2000 corresponds to  65% of individuals currently alive. Most of these individuals have retained 
specific immunodeficiencies masked by medical progress.
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scan. In 2004, the major gene was
found to correspond to the regula-
tory  region shared by 
 
PARKIN
 
 and
 
PACRG
 
 (Parkin coregulated gene),
genes that are normally coexpressed in
mononuclear phagocytes and Schwann
cells (19). 
 
PARKIN
 
 encodes an E3-
ubiquitin ligase, revealing the involve-
ment of an unexpected immunological
pathway in immunity to 
 
M. leprae
 
—an
invaluable finding in the absence of an
animal model of leprosy. Many other
infectious diseases are controlled by
major genes, which affect susceptibility
to disease at different points, including
during the initial infection and during
the development of clinical disease. For
example, levels of infection by 
 
Schisto-
soma mansoni
 
 are controlled by a major
gene on chromosome 5q (20) and the
development of liver disease is con-
trolled by another major gene on chro-
mosome 6q (21). Both genes remain to
be identified.
 
Other susceptibility genes
 
The term minor gene may be inappro-
priate for other susceptibility genes that
are not found by linkage studies, as
some may have a strong impact on the
development of infectious diseases, pos-
sibly even equal to that of major genes
in terms of relative and attributable risks
at the individual and population levels,
respectively (Fig. 2). This is best illus-
trated by the discovery that heterozy-
gous carriers of the sickle cell trait are
more resistant to severe forms of 
 
Plas-
modium falciparum
 
 malaria than individu-
als homozygous for the wild-type he-
moglobin allele (22). This observation,
made by Anthony C. Allison in 1954
from an association study based on epi-
demiological surveys, marked the birth
of the field of complex genetic suscepti-
bility and resistance to common human
infectious diseases (23). It indicated that
infectious diseases have a profound im-
pact on the natural selection of our
genome, with the sickle cell trait reach-
ing a frequency of up to 15% in en-
demic areas. However, in general, can-
didate genes selected on immunological
grounds have since failed to reveal asso-
ciations of a similar level of importance.
Countless association studies have gen-
erated weak and/or irreproducible re-
sults, with little or no biological valida-
tion of the findings. Despite scarce
molecular evidence, the polygenic hy-
pothesis of human predisposition to
infectious diseases has continued to
predominate. According to this view,
genetic susceptibility to infectious dis-
eases results in each individual from the
sum of common mutations in multiple
genes, each mutation having a modest
impact. Nevertheless, truly polygenic
inheritance may be mimicked at the
population level by numerous Mende-
lian traits or major genes, each affecting
a small number of individuals and/or
specific groups of individuals (24).
 
Mendelian resistance to infection
 
Interestingly, molecular evidence that
most humans are genetically predis-
posed to infectious diseases has been
provided by three studies disclosing the
genetic basis of Mendelian resistance to
virulent infectious agents. These studies
showed that inborn errors of immunity
do not necessarily correspond to muta-
tions, as wild-type alleles may them-
selves be highly deleterious if they
encode ports of entry for microbes.
Furthermore, bona fide mutant alleles
Figure 2. Variations in protective immunity to infection can be described at the genetic, 
cellular, individual, and population levels. Typically, rare susceptibility alleles are loss-of-function 
or hypomorphic, and are associated with a complete or partial cellular defect and a Mendelian disorder. 
Common susceptibility alleles may be hypomorphic or even wild type and associated with a subtle or 
normal cellular phenotype and a complex disease. The effects of rare and common alleles on individuals 
are generally specified in terms of clinical penetrance and relative risk, respectively. Denoting d as the 
wild-type allele and D as the deleterious allele, there are three penetrances, fdd, fDd, and fDD, defined as 
the probability of clinical disease for individuals with dd, Dd, and DD genotypes, respectively. There are 
two relative risks (RR), defined as the variation in the risk of clinical disease for Dd and DD individuals, com-
pared with dd individuals, that can be computed from penetrances as RRDd   fDd/fdd and RRDD   fDD/fdd. 
The impact of these alleles at the population level can be measured in terms of attributable risk, as 
defined by the proportion of observed cases with infectious disease that would have been avoided if 
no one in the population were carrying the genotype(s) at risk, and computed from RRs and genotype 
frequencies. Therefore, for a common infectious disease common susceptibility alleles may lead to 
high levels of attributable risk despite their moderate individual effect (RR   2–3), whereas rare al-
leles with strong individual effect (high clinical penetrance, e.g., RR   100) show little impact at the 
population level. There is, however, a continuous spectrum between these two poles in terms of allele 
frequency and impact on cellular phenotype, clinical penetrance, relative risk, and attributable risk. 
There are many intermediate situations, such as that observed with major genes that may display 
substantial effects at all levels, at least in some populations.
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that are intrinsically deleterious at the
cellular level may be beneficial at the
individual and population levels upon
microbial exposure. Autosomal reces-
sive deleterious mutations in 
 
DARC
 
(25, 26), 
 
CCR5
 
 (27–29), and 
 
FUT2
 
(30) are associated with protective im-
munity to 
 
Plasmodium vivax
 
, HIV, and
noroviruses, respectively. These genes
encode key cell surface receptors for
the corresponding pathogens on eryth-
rocytes, CD4 T cells, and intestinal ep-
ithelial cells, respectively. These muta-
tions prevent the entry of pathogens
into their principal target cell, thereby
preventing replicative host infection.
These mutant alleles do not seem to
decrease the overall fitness of people
who are homozygous or compound
heterozygous, and their expansion in
human populations may have been fa-
vored by the selective advantage they
confer in terms of protection against
the corresponding organism (DARC)
or other, as yet unknown, infections
(CCR5 and perhaps FUT2). It is clear
that individuals homozygous for the
wild-type 
 
DARC
 
, 
 
CCR5
 
, and 
 
FUT2
 
alleles are intrinsically immunodeficient
with regard to particular pathogens,
whereas mutant individuals display
greater immunity to these pathogens,
with no apparent fitness cost. How-
ever, some of the patients with these
mutations may, perhaps, be vulnerable
to other, as yet unknown pathogens. In
any event, there are probably many
other similar human mutations, which
have been or are being selected because
they confer Mendelian resistance to
virulent pathogens.
 
Multiple errors of immunity
 
There are thus multiple forms of ge-
netic predisposition to infection in hu-
mans (Fig. 2; reference 4). The fields of
primary immunodeficiencies and of
host susceptibility to infection have fol-
lowed parallel paths since the early
1950s. Work on susceptibility to infec-
tion converged with Mendelian genet-
ics in 1996, with the first successful
identification of a major locus for schis-
tosomiasis by genome-wide scan (20).
In the same year, research on primary
immunodeficiencies converged with
studies on host susceptibility to infec-
tion, with the identification of inter-
feron-
 
 
 
 receptor 1 (IFN
 
 
 
R1) muta-
tions in patients with MSMD, a
nonconventional primary immunodefi-
ciency (14, 15). There has since been
considerable cross talk between these
fields, and it is expected that they will
eventually merge, as they tackle the
same question from the complemen-
tary angles of individuals and popula-
tions: which inborn errors make us
vulnerable to infection? The more re-
cent field of Mendelian resistance to
infection, founded by Louis H. Miller
in 1976 with the discovery of Mende-
lian resistance to 
 
P. vivax
 
 (25), has also
blossomed since 1996 (26–29). It is
now clear that many genotypes and
cellular phenotypes are associated with
predisposition to clinical infectious dis-
eases at the individual and population
levels (Fig. 2). Human predisposition
to infection reflects highly diverse situ-
ations, ranging from exceedingly rare
mutations with high penetrance in in-
dividuals to common mutations ac-
counting for high attributable risk in
populations. Moreover, a variety of
genes are involved, mirroring the di-
versity of the microorganisms repre-
senting a threat.
 
Immunity at individual and 
population levels
 
The human immune system is efficient
at the species level, having allowed re-
production for 
 
 
 
200,000 years despite
the tremendous abundance and diver-
sity of environmental, commensal, and
parasitic microbes. Overall, our species
is immunocompetent but it is most un-
likely that there has ever been a truly
immunocompetent individual who was
resistant to all pathogens. The immune
system does well at the population level
but poorly at the individual level be-
cause it faces a living, rapidly dividing,
highly diverse, and coevolving parasitic
environment. At the individual level it
fails much more frequently than other
physiological systems. Each novel mi-
croorganism poses a new challenge,
and such microorganisms are arising
much more rapidly than resistant hosts.
Inborn errors of immunity are there-
fore—unfortunately but inevitably—
the rule rather than the exception. De-
spite a gradual evolutionary adjustment
of our immune genes, most individu-
als remain intrinsically vulnerable to
present and, to an even greater extent,
future infectious diseases. The recent
increase in human life expectancy re-
flects the intellectual conquests of hy-
giene, vaccines, and antibiotics. These
discoveries were based on our under-
standing of general principles of micro-
biology and immunology. Deciphering
the genetic basis of impaired immunity
to specific infections is a new frontier
that should drive further progress in
human health. Understanding the fail-
ures of the immune system should
make it possible to devise novel ways
of making it succeed.
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